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Purpose. In type 2 diabetic patients affected by chronic shoulder pain, subacromial injectionwith corticosteroid could be an effective
treatment. The aim of this study was to measure the risk-benefit ratio of this treatment. Methods. Twenty patients with well-
controlled diabetes were included in a prospective study. In a first preinjection phase, patients were asked tomeasure glycemia for 7
days, before breakfast and dinner, and then 2 hours after lunch and dinner. Baseline data including Constant Score (CS), Subjective
Shoulder Value (SSV), and Numerical Rating Scale (NRS) for pain were collected. Patients were treated with subacromial injection
with 40mg of Methylprednisolone Acetate and 2ml of Lidocaine. At discharge, patients were asked to remeasure glycemia for the
following week. Results. The overall pain improved and patients graded their shoulder as “greatly improved”. At 30-day follow-up,
the SSV and the CS improved, considering pain but not ROM.The average daily glycemia was 136mg/dl before injection, 161mg/dl
the day of the injection (p<0.001), and 170mg/dl one day after injection (p<0.001). Glycemia was not statistically different 3 days
after injection.Conclusion. Subacromial injection is an effective short-term treatment in type 2 diabetic patients affected by shoulder
pain, but a closed follow-up is recommended in all these patients. This trial is registered with NCT03652480. The Protocol ID is
SHOULDERDM2013.
1. Introduction
Among the conservative strategies to treat shoulder pain,
the use of corticosteroids in the subacromial space has been
shown to be particularly effective and safe. One of the main
limitations for the use of the corticosteroid injections remains
the potential effect on blood glucose levels especially in
diabetic patients. On the other hand, diabetic patients with
noncontrolled shoulder pain could have a major benefit from
a corticosteroid injection due to the increased risk of surgical
complication: they are often elderly patients, affected by other
severe comorbidities, and are strongly reticent to undergo
any type of surgery. Nevertheless, they often ask for a rapid,
even if temporary, pain relief solution and injection with
corticosteroids could be an effective option.
The use of corticosteroids in joints, other than the
shoulder, has been widely documented in nondiabetic and in
diabetic patients, proving to be safe and effective [1–5]. How-
ever, only two studies focused on the painful shoulder and
both of them included patients affected by adhesive capsulitis
treated with intra-articular corticosteroid injection: the risk
of hyperglycemia after injection seemed to be negligible [6, 7].
In our clinical practice, we have observed that (1)
diabetic patients with subacromial pain respond very well
to subacromial corticosteroid injections in terms of pain
relief, but the effect on range of motion (ROM) seems to be
unpredictable; (2) some patients report high levels of blood
glucose after subacromial injections, an increase that seems to
be different fromwhat has been reported after intra-articular
injections. The goal of our study was to document the effect
of subacromial corticosteroid injections on blood sugar levels
and short-term clinical outcomes in patients affected by type-
2 diabetes, not suitable for surgery and nonresponsive to
other conservative treatments.
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Figure 1: Timeline of the study protocol.
2. Methods
From 2013 to 2014, thirty consecutive type 2 diabetic patients
were initially included in this analytic prospective study
(level of evidence III). Patients examined in our outpatient
department, complaining of chronic shoulder pain resistant
to at least 6 months of conservative therapy (NSAIDs,
painkillers, and physiotherapy), were considered eligible for
this study (Figure 1).
To be included in the study, patients needed to have a
recent (within 6 months) X-ray and an MRI or ultrasound of
the affected shoulder. Other inclusion criteria were as follows:
(i) Consent to participate in the study.
(ii) Severe overall pain and night pain: Numerical Rating
Scale (NRS) for pain [8] above or equal to 60/100; the
scale wasmodified from0-10 to 0-100 (0 = no pain 100
= unbearable pain).
(iii) No significant improvement after at least 2 courses
of physiotherapy (including direct assistance from
a physical therapist with specific exercises, manual
therapy, and physical agents in order to reduce inflam-
mation and pain).
(iv) Clinical signs of subacromial tendinobursitis, with or
without signs of rotator cuff tear, defined as positive
Neer, Yocum, and Hawkins tests [9–15]. Pain experi-
enced during the execution of these tests needed to
reproduce the type of pain that patients complained
the most.
(v) No indication for surgery due to the age, concomitant
comorbidities, or patient’s refusal to undergo surgery.
(vi) Well-controlled type 2 diabetes, defined as follows
[16]:
(a) Fasting and preprandial blood glucose levels in
the range of 90-150mg/dL.
(b) Hb1Ac <64mmol/mol (corresponding to 8%)
measured within 6 months.
(vii) A device for self-measurement of blood sugar levels
at home.
Exclusion criteria were as follows:
(i) Corticosteroid treatment in the past 3 months.
(ii) Complaints of shoulder stiffness more than shoulder
pain.
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(iii) Symptomatic glenohumeral arthritis defined as
shoulder stiffness plusmoderate radiographic signs of
arthritis (grade>2 according toHamada classification
[17] and grade >1 according to Samilson-Prieto
classification for eccentric and concentric arthritis,
respectively [18]).
(iv) Shoulder trauma within 3 months of inclusion evalu-
ation for in this study.
(v) High blood pressure values (systolic blood pres-
sure >140mmHg, diastolic blood pressure >80mmHg
[16]).
(vi) Glaucoma [19].
After an initial screening, patientswere included in a prestudy
phase and baseline data were recorded, including type of
antidiabetes medications, range of motion (ROM), overall
and night pain (NRS), Constant Score (CS) [20, 21], Oxford
Shoulder Score (OSS) [22, 23], and Subjective Shoulder Value
(SSV) [24].
Moreover, we asked the patients to measure their
glycemia 4 times a day (before breakfast [fasting glycemia],
2 hours after lunch, before dinner [preprandial], and 2
hours after dinner) for one week after the first examination.
These data were used as control values and to confirm that
patients had well-controlled diabetes. In this prestudy phase
patients did not receive any injection, but only NSAIDs and
painkillers were prescribed. Ameasurement of Hb1Ac for the
patients that did not have one recent blood test (within 6
months) was also prescribed.
A subsequent examination was scheduled after one week
(Figure 1) when the principal investigator focused on the
average fasting glycemia the week before the consultation and
on the Hb1Ac. Hence, patients were either kept in the study or
excluded if the diabetes was not under control. Patients with
a mean fasting blood glucose of 90-150mg/dl and Hb1Ac<8%
were included in the study. Patients were excluded if shoulder
pain subsided after NSAIDs and painkillers previously pre-
scribed
After discussing the risks and benefits of the therapy, a
subacromial injection of Methylprednisolone Acetate 40mg
(Depo-Medrol©) and 2ml of Lidocaine 2% was performed
the morning of day 7. The same expert shoulder surgeon
performed the injections using the posterior approach to the
shoulder [25, 26]. The portal was located 1 cm inferior to
the posterolateral border of the acromion. The needle was
directed slightly superiorly, anteriorly, and medial toward
the subacromial space. An ultrasound monitoring of the
injection was not performed. Immediate, partial pain relief
due to the Lidocaine indirectly confirmed the correct site of
injection.
Patients were asked to continue the same regimen of
physical activity, rehabilitation, and antidiabetesmedications.
Patients were informed of the probable increasing of blood
glucose levels and were asked to cut down on saturated fats,
salt, and sugars. Severe hyperglycemia was defined as a single
value of fasting/preprandial glucose blood levels higher than
250mg/dL or postprandial glucose blood levels higher than
300mg/dL. Patients were also asked to report any abnormal
symptoms or signs (systolic and diastolic blood pressure,
respectively, over 140mmHg and 80mmHg [16], nausea,
erythema, itching, or vomiting). Patients were requested to
stay in the clinic for 30minutes after the injection to diagnose
any immediate adverse reaction. After the injection, patients
were requested again tomeasure and record their blood sugar
levels 4 times a day for the following 7 days. After 30 days,
a follow-up examination was scheduled in our outpatient
clinic.
At follow-up, outcomes were evaluated by using the CS,
OSS, Subjective Outcome Determination (SOD) score [27,
28], and SSV. The questionnaires were filled out in the clinic.
If patients reported insufficient pain relief or the recurrence of
shoulder pain, a second subacromial injection was proposed.
In this situation, the patient was not excluded from the study
but we asked the patient to again measure their blood sugar
levels 4 times a day.
Six months after the injection, a telephone interview was
performed to assess pain, OSS, and SOD score.
The study was approved by the Institutional Review
Board of our Hospital (Prot. CS/488) and have therefore
been performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki. All persons gave
their informed consent prior to their inclusion in the study.
2.1. Statistical Analysis. A power analysis was performed. A
significant reduction of the overall pain was considered as
principal outcome. Eighteen patients were required for an
expected reduction of 30 points of pain, with 𝛼: 0.05 and 𝛽:
0.2. The data collected were analyzed with Student’s t-test,
Fisher test, and the McNemar test for paired proportions.
The blood glucose levels at each different time point were
compared to the baseline levels (i.e., 7 days prior to the
injection) using the Student’s t-test. All the collected vari-
ables had a normal distribution except the SOD score. The
D’Agostino-Pearson test for normal distribution rejected a
normal distribution for the SOD score. The median of SOD
score was therefore reported.
3. Results
Five out of 30 patients were excluded in the prestudy phase,
since their diabetes was not well controlled. An additional
5 patients were excluded because they did not adequately
record their glycemia after the injection (2 patients) or did
not come back for the follow-up examination (3 patients).
The 3 patients lost to follow-up were contacted by phone and
they stated a significant improvement after injection. Twenty
patients were ultimately included in the study. One patient
was subsequently lost to follow-up at 6 months during the
telephone interview phase. This patient was not excluded
since the majority of the data important for the study were
available for the analysis.
The average age was 71 years (63-83), 12 patients were
female, 7 were managing their diabetes with insulin therapy,
and 13 were doing so with oral diabetes medications. The
average baselineCSwas 43±12, theOSS 28±8, and theNRS for
pain 76±11. All the patients had positive tests for subacromial
tendinobursitis. Four patients had a concomitant adhesive
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Figure 2: Preinjection and postinjection Constant Score (CS). The figure shows the improvement of the CS after subacromial corticosteroid
injections. The improvement is significant (∗= p<0.05) for the overall CS and for the pain item. Details regarding night pain are reported in
Figure 3.
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Figure 3: Preinjection and postinjection night pain. A significant
improvement in night pain was recorded in the study. The rate of
patients who experienced nightly pain decreased after the injection.
Simultaneously, the rate of patients that did not have night pain
increased to 61% after the injection.
capsulitis. The imaging studies showed a cuff tear involving
the supraspinatus in 12 patients, a massive cuff tear involving
the infraspinatus and supraspinatus in 4 patients. Four
patients had mild signs of eccentric osteoarthritis (Hamada
[17] stages 1 and 2).
3.1. Efficacy. At 30 days of follow-up a statistically significant
improvement of the CS was reported, from 43±12 to 52±13
(p=0.008). The improvement in CS was more relevant con-
sidering the pain component of the score (Figures 2 and 3).
The variables, strength, ROM, and Work/ADL, did not
improved significantly after the injection.
An improvement was also measured using the OSS but
was only significant at 6 months (Figure 4).
The overall pain improved from 76±11 to 44±22 (p<0.001)
at 30-day follow-up and to 38±30 at 6-month follow-
up (p<0.001). However, the improvement in overall pain
between 30 days and 6 months was not significant (p=n.s.).
Nightly pain was reduced from 78±10 to 35±19 (p<0.001) at
30 days and to 31±25 (p<0.001) at 6-month follow-up. The
improvement in nightly pain levels between 30 days and 6
months was not significant (p=n.s.).
The SSV preinjection was 49±14; it improved to 64±19
thirty days after injection (p=0.001) and to 68±25 (p<0.001)
at 6-month follow-up. Again, the improvement between 30
days to 6 months was not statistically significant (p=n.s.).
One month after injection, the clinical improvement was
also shown by a median SOD score of 6 points (= “Greatly
Improved”). The median SOD value at 6 months remained 6
points.
During the study period, 5 patients asked for a second
subacromial injection.
3.2. Safety. The average daily blood glucose levels are
reported in Figure 5. Blood glucose levels were not statisti-
cally different after 3 days after injection. After 5 days blood
glucose levels were normal.
Figure 6 shows that the details of the blood glucose levels
increase the day of and the day after the injection. An increase
of blood sugar levels was observed the day of and the day after
the subacromial injection.
Five patients (25%) had severe hyperglycemia: 2 patients
had one episode of fasting/preprandial glycemia >250mg/dL
the day after the injection, 2 patients had a postprandial
glycemia >300mg/dL (330 and 308mg/dl), 1 patient had
one episode of fasting glycemia of 265mg/dL followed by
a postprandial glycemia of 304mg/dL. All the episodes of
severe hyperglycemia were recorded the day and the day after
the injection. Three out of these 5 patients were managing
their diabetes with oral medications.
A posthoc analysis of the patients that experienced severe
hyperglycemia revealed that they had an average preinjection
fasting glycemia worse than the patients who were not
affected by this complication (137mg/dl, range 113 to 150
versus 122mg/dl, range 84 to 150).
One patient reported insomnia the night of the injection
not related to shoulder pain. No other complications were
reported.
4. Discussion
The aim of this prospective study was to report the short-
term benefits and the effects on glucose blood levels of a
subacromial injection with corticosteroids in type 2 diabetic
patients affected by severe shoulder pain, not responsive to
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injection (p<0.001).
conservative treatment and not suitable for surgery.Themost
important finding is that the injection significantly reduced
the overall pain and the night pain and most of the patients
had a perception of a greatly improved shoulder at 1- and 6-
month follow-up.
These data were consistent with previous reports. Yu [29]
showed, in a prospective clinical study conducted on 238
shoulders, a significant improvement of the quality of life
and of the ROM in 91% of cases 1 month after the injection
with 1ml of Xylocaine 2% and 1ml of Betamethasone. One
year later, the improvement was still significant in 88% of
the treated patients. Akgun [30] highlighted a substantial
improvement of shoulder symptoms, by using the CS 1month
after injection, duemoreover to the reduction of pain at night.
In contrast to what has been reported previously, we
did not observe a significant improvement in ROM and
function after subacromial injection. The reason could be a
difference in the patient population included in this study.
We included older diabetic patients affected by shoulder pain
with multiple etiologies including rotator cuff tears and mild
osteoarthritis.Moreover, despite the fact that a clear diagnosis
of adhesive capsulitis was present in only 4 cases, we cannot
rule out the possibility that some of the patients had some
minor forms of adhesive capsulitis secondary to diabetes
[31, 32].The infiltration could have improved the pain related
to subacromial tendinobursitis and long head of the biceps
inflammation but perhaps was unable to improve the ROM
mostly due to an inflamed and tight capsule secondary to
adhesive capsulitis or osteoarthritis.
The second finding was the effect of subacromial injec-
tions on blood glucose levels in type 2 diabetic patients.
Overall, the infiltration increased the average glycemia for
three days, with a peak the day after the injection. No
hyperglycemia-related symptoms were recorded. Although
these data can be considered generally a good result, they
must be interpreted with extreme caution. Twenty-five per-
cent of the patients had a transitory severe hyperglycemia.
These data are in contrast with the study of Habib [6]
who showed that there is no significant change in blood
glucose levels after injecting 35mg of Methylprednisolone
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Acetate at the shoulder joint. The reason for this difference
is unknown. One potential explanation is that the effect
on blood glucose levels of an intra-articular injection of
Methylprednisolone Acetate is different from a subacromial
injection. The absorption of the corticosteroids could be
higher and faster in the inflamed subacromial bursa. Other
reasons could be due to, in our study, 40mg instead of 35mg
of Methylprednisolone Acetate being injected and that the
corticosteroid was associated with Lidocaine.
Interestingly, in our series the patients that had severe
hyperglycemia had had a suboptimal fasting glycemia before
the injection. This data could imply that a better control
of diabetes should prevent postinjection hyperglycemia and
improve the safety of the treatment with corticosteroids.
The comparison of our results with other studies [1–
3, 5, 6, 33] revealed that the effect of corticosteroid injections
in other joints is also a variable and in some cases can
significantly increase the blood glucose levels. Habib [1]
reported a short glycemia increase only the first day after
Celestone Chronodose in 6 knees of patients affected by
type 2 diabetes. In 30 diabetic patients who underwent an
injection with Triamcinolone Acetonide and Triamcinolone
Esacetonide, a highly variable increase in glycemic values was
reported (always below 300mg/dL). Zufferey [5] reported no
change in blood glucose levels among patients who received
an epidural injection with 80mg of Methylprednisolone
Acetate, while patients who underwent an injection in their
knees or shoulders with the same drug recorded an increase
of glycemia, with a high individual variability.
One option for the treatment of persistent shoulder pain
in diabetic patients is the injection with hyaluronic acid.
However, the effect of this injection in diabetic patients has
never been proven effective. Three patients in our study
cohort have been injected with hyaluronic acid before being
included in our study. None of them had reported a signifi-
cant improvement.
Penning [34] compared subacromial Triamcinolone Ace-
tonide, hyaluronic acid, and placebo for shoulder pain: he
observed a booster effect in pain reduction after repeated
Triamcinolone Acetonide injections. The hyaluronic acid and
placebo group showed only slight improvements in pain
reduction.
This study has some limitations. The injections were
performed without use of ultrasound guidance. A study,
however, showed that there is little evidence for the need
of ultrasound guided needle placement [35]. Our patients
reported an immediate slight to moderate benefit from the
injection, indirect proof that the injection, that contained
Lidocaine, was performed correctly. Another limitation is
that we included diabetic patients with resistant shoulder
pain, regardless the type of diagnosis. The main goal of this
study was to test the short-term benefit of corticosteroid
injections on pain. Shoulder pain, in old patients, has amulti-
factorial etiology. For this reason, we preferred to include all
the patients with pain and not only those affected by a specific
pathology. Future studies should address the risk-benefit ratio
of corticosteroid injections in specific pathologies.
5. Conclusions
Subacromial injection with 40mg of Methylprednisolone
Acetate is effective as a short-term treatment in type 2 diabetic
patients affected by shoulder pain. Patients must be informed
about the possibility of transient hyperglycemia for the 3 days
after injection and that 20% could have a transient severe
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hyperglycemia, especially the day of and the day after the
injection and they must be closely followed up.
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